drugset / Trial / NCT00123227
Rosiglitazone Plaque Study
Phase 3
Unknown
60 enrolled
Royal Brompton & Harefield NHS Foundation Trust
CORDA, The Heart Charity · collabGlaxoSmithKline · collab
RandomizedSingle-groupDouble-blindTreatment
Summary
The purpose of this study is to determine whether rosiglitazone, a peroxisome proliferator activated receptor gamma (PPAR-gamma) agonist, induces regression in carotid atherosclerotic plaques in diabetic patients with vascular disease and/or hypertension over a 12 month period.
Timeline
- Start
- 2002-10
- Primary completion
- —
- Completion
- 2005-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rosiglitazone | Small molecule | — | — |